GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Insider Ownership

Incanthera (AQSE:INC) Insider Ownership : 0.00 % (As of Jun. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Incanthera's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Incanthera's Institutional Ownership is 2.75%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Incanthera's Float Percentage Of Total Shares Outstanding is 0.00%.


Incanthera Insider Ownership Historical Data

The historical data trend for Incanthera's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Insider Ownership Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Insider Ownership
- - - -

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Insider Ownership Get a 7-Day Free Trial - - - - -

Incanthera Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines